Medical oncologist specialized in genitourinary cancers. Associate editor, ESMO Rare Cancers. Tweets are my own views, and are not medical advice.
Orange County, CA
Joined April 2021
- Tweets198
- Following305
- Followers601
- Likes7.2K
Pinned Tweet
Was a pleasure to talk with @RinaNakanoTV of @kcalnews @CBSNews about our @JCOOP_ASCO publication on cancer's portrayal in #movies.
Several aspects including #cancer type, treatment and prognosis significantly diverge from reality.
Link (video): cbsnews.com/losangeles/video…
Can we improve androgen deprivation therapy for treating prostate cancer?
In @EurUrolOncol, @ArashRezazadeh6 and I discuss the data for transdermal estradiol (tE2) patch.
Despite a phase III study being published several months ago, tE2 remains absent from treatment guidelines.
There are several advantages to tE2 including less hot flashes, less negative effect on bone health, and less financial toxicity.
Link (free text): authors.elsevier.com/a/1nkp9…
David J. Benjamin, MD retweeted
Cancer trials enroll more women but rarely compare outcomes by sex, leaving safety gaps and urging equity-focused study design. 🔬
📝 @DavidBenjaminMD (@hoaghealth) writes for Targeted Oncology: targetedonc.com/view/more-ca…
#ClinicalTrials #HealthEquity #CancerResearch #Oncology
Can we refine & improve upon our efforts to increase representation of #women in #cancer clinical trials?
In @NatRevUrol, we discuss the importance of incorporating sex-specific variables in order to better understand efficacy and toxicity of cancer therapies in women.
Link (free access): rdcu.be/foFl0
Thankful to @myESMO for the opportunity to present our study with co-authors @kjmeetswrld @DrMarkLythgoe at #ESMO25 on the state of the global medical oncology workforce.
We identified a total of 82,995 medical oncologists in practice across the globe.
Disparities exist in accessing an oncologist particularly in lower middle- and low-income countries.
David J. Benjamin, MD retweeted
🧵 1/
Proud to finally share a paper that took a great deal of effort to write and get published.
A global survey sent to 600+ uro-oncologists, with 201 responses from over 30 countries, exploring real-world use of enfortumab vedotin + pembrolizumab (EV-P) in metastatic urothelial carcinoma. 😊 One of the largest initiatives of its kind to date. 🌍
academic.oup.com/oncolo/adva…
@UroDocAsh @OncoBellmunt @ProfSyedHussain @AlisonBirtle @raymanneh @dmukherji @amerseburger @DrIacovelli @giannatempopatr @DrYukselUrun @BourlonMaite @cdanicas @DrFelixGuerrero @mflazzaro_gu @ravikanesvaran @DrBenTran @OncoAlert @Larvol @_SEOM @myESMO @urotoday
Thank you @CancerTodayMag @AACR for featuring our recent @myESMO Real World Data & Digital Oncology study on the portrayal of cancer in public figures in news stories.
The public should be cognizant that many news articles lack pertinent details on an individual's diagnosis, prognosis and treatment. This may create unnecessary stress due to the lack of details and general uncertainty in these articles.
CC: @drenriquegrande @montypal @PGrivasMDPhD @ArashRezazadeh6
#ICYMI: What you don’t know about celebrity cancer stories can cause confusion about your own risks or treatment. brnw.ch/21wT46N
David J. Benjamin, MD retweeted
@DavidBenjaminMD of @hoaghealth, discusses how he uses real-world data to supplement clinical trial results in urothelial carcinoma.
Read the full article here: hubs.li/Q03rq-MJ0
David J. Benjamin, MD retweeted
Real-World Data Help Fill the Gaps Left by Clinical Trial Results in Urothelial Carcinoma @DavidBenjaminMD #blcsm hubs.li/Q03rkD3C0
Is the field of genitourinary oncology pivoting away from precision medicine -- and towards imprecision?
In @BJUIjournal, @ArashRezazadeh6 and I cite two recent examples of TALAPRO-2 (for metastatic hormone resistant prostate cancer) and EV-302 (for advanced urothelial carcinoma).
Both had conference updates suggesting no role for biomarkers despite pre-clinical and trial data suggesting otherwise. This is timely given the FDA ODAC's vote against TALAPRO-2 last week.
Our field is at a critical juncture in deciding whether to use biomarkers to pair the right treatment with the right individual.
Link: bjui-journals.onlinelibrary.…
BREAKING: The FDA’s ODAC deemed the results from TALAPRO-2 insufficient to conclude a favorable benefit-risk profile for adding talazoparib to enzalutamide in non-HRRm #mCRPC in an 8 to 0 vote.
hubs.li/Q03nFR900
David J. Benjamin, MD retweeted
RWE is crucial for our daily clinical practice! What insightful discussions on mUC treatments! Balancing QoL with efficacy is the key! @drenriquegrande @DavidBenjaminMD
Congratulations to my mentor @ArashRezazadeh6 on receiving the 2025 @UCIMedSchool Faculty Mentor of the Year Award!
There is no more deserving individual I know who mentors faculty and trainees across multiple specialities and institutions.
Fortunate and grateful for your mentorship, Dr. Rezazadeh!
David J. Benjamin, MD retweeted
@TheLancetOncol Comment: As cancer therapies evolve, sexual & reproductive #Toxicity remains underreported. Experts like @DavidBenjaminMD call for integrating #Oncofertility into routine care—especially for younger patients. bit.ly/4lwGBET #ReproductiveHealth
Is the field of oncology overlooking sexual health and reproductive toxicities from cancer therapies?
In @TheLancetOncol, @DrMarkLythgoe and I highlight two recent examples, and call for improved monitoring & reporting in clinical trials.
Many thanks to the editorial team for selecting our commentary as an Editor's Pick for the April issue.
Link: thelancet.com/journals/lanon…
David J. Benjamin, MD retweeted
🧨Great to be editors pick in @TheLancetOncol this month for our comment....highlighting Sexual health and reproductive toxicity from cancer therapies
thelancet.com/journals/lanon…
@DavidBenjaminMD @ImperialSandC @pash22 @SullivanProf @oncology_bg @darioT_ @SuyogCancer @BMJOncology
How many genitourinary medical oncologists are in the US, and where (region, practice setting, etc.) do they practice?
In @urogoldjournal, we find that there are a total of 451 GU medical oncologists in the US, most of whom are men (72.5%).
The majority of GU medical oncologists practice in academia (88.5%).
In addition, most GU medical oncologists practice in the Northeast followed by the South, West, and Midwest. Of note, seven states have no GU medical oncologist.
Link (full text): authors.elsevier.com/a/1kiAn…
David J. Benjamin, MD retweeted
One of the highlights of #SoCalGU25 was our inaugural poster session. Congrats to our poster sessions winners, #DrFarzadTeymouri, @gonzales_neekz & @MazyarZahir - equally deserving are their mentors @ArashRezazadeh6 @UCIrvine, @DavidBenjaminMD @hoaghealth, @EdwinPosadasMD, @jgong15 @CSCancerCenter & @siadaneshmand @USC_Urology. Please mark your calendar for Feb 13, 2026 for #SoCalGU26!
David J. Benjamin, MD retweeted
Our paper is out: I found this interesting
Some cancers celebs are more likely to admit to having than others. Above the line is over represented reporting in media.
Does reading an article about a public figure with cancer leave you with more uncertainty than clarity?
In @myESMO Real World Data and Digital Oncology, we review news articles about public figures with cancer from 2010 to 2020.
Our study found that most articles lack pertinent details (e.g. type, prognosis, treatment, etc.) on cancer care. Understandably, public figures may choose not to disclose personal aspects of their cancer care.
The lack of details and general uncertainty about cancer in these public figures may ultimately lead to more fear and anxiety among readers.
CC: @VPrasadMDMPH @vkprasadlab @ArashRezazadeh6
Link (full text): esmorwd.org/article/S2949-82…
Does reading an article about a public figure with cancer leave you with more uncertainty than clarity?
In @myESMO Real World Data and Digital Oncology, we review news articles about public figures with cancer from 2010 to 2020.
Our study found that most articles lack pertinent details (e.g. type, prognosis, treatment, etc.) on cancer care. Understandably, public figures may choose not to disclose personal aspects of their cancer care.
The lack of details and general uncertainty about cancer in these public figures may ultimately lead to more fear and anxiety among readers.
CC: @VPrasadMDMPH @vkprasadlab @ArashRezazadeh6
Link (full text): esmorwd.org/article/S2949-82…
David J. Benjamin, MD retweeted
State of the Genitourinary Medical Oncology Workforce in the United States, 2024. Presentation by @DavidBenjaminMD @hoaghealth. #GU25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4k1Mqtd @ASCO
